No Data
No Data
Companies Like Lexeo Therapeutics (NASDAQ:LXEO) Are In A Position To Invest In Growth
Lexeo Therapeutics Initiated at Outperform by Baird
Lexeo Therapeutics Initiated at Outperform by Baird
Express News | Lexeo Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Price Target $28
Lexeo Therapeutics(LXEO.US) Officer Sells US$88,263.82 in Common Stock
$Lexeo Therapeutics(LXEO.US)$ Officer Townsend Richard Nolan sold 5,000 shares of common stock on Jun 10, 2024 at an average price of $17.65 for a total value of $88,263.82.Source: Announcement What i
Baird Initiates Lexeo Therapeutics(LXEO.US) With Buy Rating, Announces Target Price $28
Baird analyst Brian Skorney initiates coverage on $Lexeo Therapeutics(LXEO.US)$ with a buy rating, and sets the target price at $28.According to TipRanks data, the analyst has a success rate of 41.1%
Lexeo Therapeutics Initiated at Buy by HC Wainwright & Co.
Lexeo Therapeutics Initiated at Buy by HC Wainwright & Co.
No Data